About this trial
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.
Eligibility criteria
Qualifiers
Admitted to UMMC for cardiac procedure
Age: >/=18 y.o TO 88 y.o.
Undergoing CPB >1hr for the following surgeries (a) complex cardiac surgery (b) heart valve replacement surgery OR (c) CABG surgery.
Disqualifiers
Pregnant
Non English speaking
Unable to consent or have Legally Authorized Representative (LAR) assent to study
Trial design
Treatments tested in this trial
- Blood and urine collection
Treatment groups
Sponsors and collaborators
University of Maryland, Baltimore
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator